If no other option help...
Key Market Indicator:
F&G: 63
25.547,95 NASDAQ · 49.390,00 DOW · 6.947,26 S&P · 4.596,86 Gold · 63,45 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE0005203947
Filter zurücksetzen
© EQS Newswire
14.01.2026
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG profitiert durch erfolgreiche Monetarisierung von Projekten und starker Kostenkontrolle
Article
News Preview
Geschäftsjahr 2024/25: BRAIN Biotech AG profitiert durch erfolgreiche Monetarisierung von Projekten und starker Kostenkontrolle Herausforderndes Absatzumfeld, starke Kostenkontrolle im Unternehmen Erfolgreiche Monetarisierung von Projekten aus der BRAINBioIncubator-Pipeline Liquiditätsbestand des Konzerns mit 6,2 Mio. EUR weiterhin solide ZWINGE......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2026
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control
Article
News Preview
FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control Challenging sales environment, but strong corporate cost control Successful monetization of projects from the BRAINBioIncubator pipeline Group’s cash position remains solid at € 6.2 million ZWINGENBERG, Germany, January 14, 2026 – BRA......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.09.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte
Article
News Preview
BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte ZWINGENBERG, Deutschland, 3. September 2025 – Die BRAIN Biotech AG, ein führender Anbieter integrierter Lösungen für die Biologisierung der Industrie, hat Johan Jansén-Storbacka mit Wirkung zum 1. September 2025 zum Executive V......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
03.09.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
Article
News Preview
BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business ZWINGENBERG, Germany, September 3, 2025 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has appointed Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocat......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
28.08.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
Article
News Preview
BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts BRAINBiocatalysts with +8.1% year-on-year revenue growth Perillic Active project from the BRAINBioIncubator segment now successfully partnered Cash position remains solid at €10.5 million ZWINGENBERG, Germany, August 28, 2025 – BRAIN Biotech AG, a leading provider ......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.08.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech mit dynamischem Q3-Umsatzwachstum im Kernsegment BRAINBiocatalysts
Article
News Preview
BRAIN Biotech mit dynamischem Q3-Umsatzwachstum im Kernsegment BRAINBiocatalysts BRAINBiocatalysts mit +8.1% Umsatzwachstum zum Vorjahr Projekt Perillic Active aus dem Segment BRAINBioIncubator erfolgreich verpartnert Weiterhin solide Barmittelposition mit 10.5 Mio. € ZWINGENBERG, 28. August 2025 – Die BRAIN Biotech AG, ein führender Anbieter v......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.08.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
Article
News Preview
Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies ZWINGENBERG, Germany, August 25, 2025 – Corbion, the global sustainable ingredients company based in Amsterdam, the Netherlands, and BRAIN Biotech AG, headquartered in Zwingenberg, Germany, have reached agreement to collaborate in the developme......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.08.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Corbion und BRAIN Biotech arbeiten gemeinsam an Technologien für naturbasierte Inhaltsstoffe der Zukunft
Article
News Preview
Corbion und BRAIN Biotech arbeiten gemeinsam an Technologien für naturbasierte Inhaltsstoffe der ZukunftZWINGENBERG, 25. August 2025 – Corbion, ein weltweit tätiges Unternehmen für nachhaltige Inhaltsstoffe mit Sitz in Amsterdam, und die BRAIN Biotech AG mit Hauptsitz in Zwingenberg, haben eine Vereinbarung zur Zusammenarbeit bei der Entwicklung ne......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.07.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG
Article
News Preview
Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG ZWINGENBERG, 23. Juli 2025 – Der Aufsichtsrat der BRAIN Biotech AG ist wieder vollständig besetzt: Dr. Ursula La Cognata wurde vom Amtsgericht Darmstadt mit Wirkung zum 11. Juli 2025 bis zur nächsten Hauptversammlung als neues Mitglied in den Aufsichtsrat bestellt. Sie ergä......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.07.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
Article
News Preview
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG ZWINGENBERG, Germany, July 23, 2025 – The Supervisory Board of BRAIN Biotech AG is once again fully staffed: Dr. Ursula La Cognata has been appointed as a new member of the 6-person Supervisory Board by the Darmstadt District Court with effect from July 11, 2025 until......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.05.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25
Article
News Preview
BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25 BRAINBiocatalysts experienced modest organic growth in the first half of the year BRAINBioIncubator with high basis for comparison in the previous year Strong liquidity maintained at €14.9 million ZWINGENBERG, Germany, May 28, 2025 – BRAIN Biotech AG, a leading provider of......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.05.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG berichtet finale Halbjahreszahlen für das Geschäftsjahr 2024/25
Article
News Preview
BRAIN Biotech AG berichtet finale Halbjahreszahlen für das Geschäftsjahr 2024/25 BRAINBiocatalysts mit leichtem organischem Wachstum im ersten Halbjahr BRAINBioIncubator mit hoher Vergleichsbasis im Vorjahr Starke Liquiditätsposition von 14,9 Mio. € Zwingenberg, 28. Mai 2025 – Die BRAIN Biotech AG, ein führender Anbieter von Spezialenzymen und i......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
20.05.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech informiert über Erwerb von Minderheitsanteilen, neue Produktionsstätte in Kontinentaleuropa und Ausbau seines Kompetenzzentrums für Backapplikationen
Article
News Preview
BRAIN Biotech informiert über Erwerb von Minderheitsanteilen, neue Produktionsstätte in Kontinentaleuropa und Ausbau seines Kompetenzzentrums für Backapplikationen Breatec B.V. nach Minderheitsübernahme nun vollständig im Besitz der BRAIN Biotech AG Neuer, vergrößerter Produktionsstandort wird in der Nähe von Eindhoven, NL, eröffnet Erweitertes......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.05.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
Article
News Preview
BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center Breatec B.V. is now fully owned by BRAIN Biotech AG following a minority buyout New and enlarged production site will open close to Eindhoven, NL Expanded competence center for enzyme-based baking applications Z......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.04.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
Article
News Preview
BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25 Zwingenberg, Germany, 30 April 2024 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) today reports preliminary Q2 figures for the financial year 2024/25 with Q2 revenues of EUR 12.12 million and a......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.04.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG gibt vorläufige Zahlen für das zweite Quartal bekannt und prognostiziert eine konservativere Entwicklung für das zweite Halbjahr des Geschäftsjahres 2024/25
Article
News Preview
BRAIN Biotech AG gibt vorläufige Zahlen für das zweite Quartal bekannt und prognostiziert eine konservativere Entwicklung für das zweite Halbjahr des Geschäftsjahres 2024/25 Zwingenberg, Deutschland, 30. April 2025 – Die BRAIN Biotech AG (ISIN DE0005203947; „BRAIN“ oder „Gesellschaft“) gibt heute vorläufige Zahlen für das zweite Quartal des Geschä......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.03.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
Article
News Preview
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling ......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.03.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
Article
News Preview
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG ZWINGENBERG, 18. März 2025 – In der ordentlichen Präsenzhauptversammlung der BRAIN Biotech AG (Frankfurter Börse / BNN / ISIN DE0005203947 / WKN 5203949) haben die Aktionäre heute allen Tagesordnungspunkten mit einer breiten Mehrheit zugestimmt. Dr. Anna C. Eichhorn u......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.02.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
3M GJ 24/25 - Jahresauftakt mit zweistelligem Umsatzwachstum im Kernsegment BRAINBiocatalysts
Article
News Preview
BRAIN Biotech AG: 3M GJ 24/25 - Jahresauftakt mit zweistelligem Umsatzwachstum im Kernsegment BRAINBiocatalysts BRAINBiocatalysts mit 11 % organischem Wachstum im ersten Quartal Quantitative Prognose für starkes Wachstum und solide bereinigte EBITDA-Marge für BRAINBiocatalysts im Geschäftsjahr 2024/25 Starke Liquiditätsposition von 17,8 Mio. Eur......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.02.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
Article
News Preview
BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAINBiocatalysts organic growth at 11 % in Q1 Quantitative guidance looking at strong growth and solid adjusted EBITDA margin for BRAINBiocatalysts in FY 2024/25 Strong cash position maintained at € 17.8 million while reducing......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.02.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative
Article
News Preview
Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative Development of BioXtractor V2 pilot by BRAIN and PX Group and production of first BioGold nuggets from a local waste stream Extension of cooperation between the two companies as part of the PX Urban Mining Initiative PX Urban Mining Initiativ......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.02.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG kooperiert mit PX Group im Rahmen der „PX Urban Mining Initiative“
Article
News Preview
Biologisches Goldrecycling: BRAIN Biotech AG kooperiert mit PX Group im Rahmen der „PX Urban Mining Initiative“ BRAIN Biotech und PX Group entwickeln die Pilotanlage „BioXtractor V2“ und gewinnen erste BioGold-Nuggets aus lokalem Abfallstrom Beide Unternehmen weiten Zusammenarbeit im Rahmen der „PX Urban Mining Initiative“ aus Die „PX Urban Mini......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG mit starker Liquiditätsposition und zuversichtlichem Wachstumsausblick
Article
News Preview
Geschäftsbericht 2023/24: BRAIN Biotech AG mit starker Liquiditätsposition und zuversichtlichem Wachstumsausblick Verbesserung der liquiden Mittel im Konzern auf 27,2 Mio. Euro Erfolgreicher Abschluss von zwei Meilenstein-Transaktionen mit Royalty Pharma und Akribion Therapeutics Management sieht guten Start ins neue Geschäftsjahr Aktualisierun......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
Article
News Preview
Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects Group cash and cash equivalents improved to € 27.2 million Successfully closed two milestone transactions with Royalty Pharma and Akribion Therapeutics Management sees a strong start to the new financial year Updated mid-term tar......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG schärft Fokus auf profitables Wachstum
Article
News Preview
BRAIN Biotech AG schärft Fokus auf profitables Wachstum Zusammenführung von BioProducts und BioScience Zwingenberg zum Wachstumssegment BRAINBiocatalysts 5-Jahres-Ziele im Segment BRAINBiocatalysts: 100 Mio. Euro Umsatz, 15 % bereinigte EBITDA-Marge bei gleichzeitig hoher F&E-Quote Deutliche Verbesserung der Liquiditäts- und Ertragssituatio......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG Sharpens Focus on Profitable Growth
Article
News Preview
BRAIN Biotech AG Sharpens Focus on Profitable Growth Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D ratio Significant improvement in the liquidity and earnings s......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.10.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG und Akribion Therapeutics GmbH unterzeichnen exklusiven Pharma-Lizenzvertrag für G-dase E®-CRISPR-Cas-Technologie
Article
News Preview
BRAIN Biotech AG und Akribion Therapeutics GmbH unterzeichnen exklusiven Pharma-Lizenzvertrag für G-dase E®-CRISPR-Cas-Technologie Akribion Therapeutics GmbH wird von starkem Risikokapital-Konsortium (Venture-Capital-Konsortium) mit Pharma-Expertise finanziert BRAIN erhält bis zu 92,3 Millionen Euro an F&E- und kommerziellen Meilensteinzahlun......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.10.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology
Article
News Preview
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees plus additional royalties in exchange for granti......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.10.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG schließt exklusiven Pharma-Lizenzvertrag für G-dase E® CRISPR-Cas-Technologie mit Akribion Therapeutics GmbH über bis zu 92,3 Mio. Euro Meilensteinzahlungen plus Lizenzgebühren ab
Article
News Preview
NICHT ZUR VERTEILUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN DEN ODER IN DIE VEREINIGTEN STAATEN, AUSTRALIEN, KANADA, JAPAN ODER ANDERE LÄNDER, IN DER DIE VERTEILUNG ODER WEITERGABE GESETZLICH UNZULÄSSIG WÄRE. ES GELTEN ANDERE EINSCHRÄNKUNGEN. BITTE BEACHTEN SIE DIE WICHTIGEN HINWEISE AM ENDE DIESER MITTEILUNG. BRAIN Biotech AG schließt exklusiv......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.10.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties
Article
News Preview
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG signs exclusive pharma licensing ag......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.10.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Frau Prof. Dr. Wiltrud Treffenfeldt verlässt aus persönlichen Gründen den Aufsichtsrat der BRAIN Biotech AG
Article
News Preview
Frau Prof. Dr. Wiltrud Treffenfeldt verlässt aus persönlichen Gründen den Aufsichtsrat der BRAIN Biotech AG Zwingenberg, 03. Oktober 2024 – Frau Professor Dr. Wiltrud Treffenfeldt hat den Aufsichtsratsvorsitzenden sowie die weiteren Mitglieder des Aufsichtsrats der BRAIN Biotech AG darüber informiert, dass sie aus persönlichen Gründen mit Wirkung ......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.10.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
Article
News Preview
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Superv......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Article
News Preview
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an investigational compound, deucrictiban......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG verkauft Einnahmen aus Pharmawirkstofflizenz für bis zu 128,88 Millionen Euro aus seinem BioIncubator
Article
News Preview
BRAIN Biotech AG verkauft Einnahmen aus Pharmawirkstofflizenz für bis zu 128,88 Millionen Euro aus seinem BioIncubator Gesamttransaktionswert von bis zu 128,88 Mio. EUR übersteigt deutlich die aktuelle Marktkapitalisierung von BRAIN Biotech Sofortige Abschlagszahlung von 18,41 Mio. EUR Monetarisierung von Lizenzgebühren für den investigativen Wi......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Article
News Preview
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an investigational compound, deucrictiban......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG verkauft Einnahmen aus Pharmawirkstofflizenz für bis zu 128,88 Millionen Euro aus seinem BioIncubator
Article
News Preview
BRAIN Biotech AG verkauft Einnahmen aus Pharmawirkstofflizenz für bis zu 128,88 Millionen Euro aus seinem BioIncubator Gesamttransaktionswert von bis zu 128,88 Mio. EUR übersteigt deutlich die aktuelle Marktkapitalisierung von BRAIN Biotech Sofortige Abschlagszahlung von 18,41 Mio. EUR Monetarisierung von Lizenzgebühren für den investigativen Wi......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
Article
News Preview
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   BRAIN Biotech AG concludes royalty monetization d......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für den investigativen Pharmawirkstoff Deucrictibant mit Royalty Pharma ab
Article
News Preview
NICHT ZUR VERTEILUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN DEN ODER IN DIE VEREINIGTEN STAATEN, AUSTRALIEN, KANADA, JAPAN ODER ANDERE LÄNDER, IN DER DIE VERTEILUNG ODER WEITERGABE GESETZLICH UNZULÄSSIG WÄRE. ES GELTEN ANDERE EINSCHRÄNKUNGEN. BITTE BEACHTEN SIE DIE WICHTIGEN HINWEISE AM ENDE DIESER MITTEILUNG.   BRAIN Biotech AG schließt eine ......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
Article
News Preview
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   BRAIN Biotech AG concludes royalty monetization d......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für den investigativen Pharmawirkstoff Deucrictibant mit Royalty Pharma ab
Article
News Preview
NICHT ZUR VERTEILUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN DEN ODER IN DIE VEREINIGTEN STAATEN, AUSTRALIEN, KANADA, JAPAN ODER ANDERE LÄNDER, IN DER DIE VERTEILUNG ODER WEITERGABE GESETZLICH UNZULÄSSIG WÄRE. ES GELTEN ANDERE EINSCHRÄNKUNGEN. BITTE BEACHTEN SIE DIE WICHTIGEN HINWEISE AM ENDE DIESER MITTEILUNG.   BRAIN Biotech AG schließt eine ......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
Article
News Preview
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year Cash on-hand at € 13 million Significantly improved operating cash-flow in the 9M Forecasting a sequentially strong BioProducts quarter in Q4 FY 23/24 August 29, 2024, Zwingenberg/Germany – BRAI......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech präsentiert im Rahmen der 9M-Berichterstattung starke Cash-Position und prognostiziert starkes sequenzielles Wachstum im letzten Quartal des Geschäftsjahrs
Article
News Preview
BRAIN Biotech präsentiert im Rahmen der 9M-Berichterstattung starke Cash-Position und prognostiziert starkes sequenzielles Wachstum im letzten Quartal des Geschäftsjahrs Liquide Mittel bei 13 Millionen € Operativer Cashflow in den ersten neun Monaten deutlich verbessert Erwartung eines sequenziell starken vierten Quartals für BioProducts im Gesc......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.05.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
Article
News Preview
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes Zwingenberg and Greifswald, May 29, 2024 – BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as Senior Business Development Director Enzymes as of June 1st, 2024. De Vries will continue......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.05.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech gibt die Ernennung von Erik de Vries zum Senior Director Geschäftsentwicklung Enzyme bekannt
Article
News Preview
BRAIN Biotech gibt die Ernennung von Erik de Vries zum Senior Director Geschäftsentwicklung Enzyme bekannt Zwingenberg und Greifswald, 29. Mai 2024 – BRAIN Biotech AG und Enzymicals AG geben bekannt, dass Dr. Erik de Vries die BRAIN Biotech AG ab dem 1. Juni 2024 als Senior Business Development Director Enzymes unterstützen wird. Sein derzeitiges ......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.05.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech gibt die Ernennung von Erik de Vries zum Senior Director Geschäftsentwicklung Enzyme bekannt
Article
News Preview
BRAIN Biotech gibt die Ernennung von Erik de Vries zum Senior Director Geschäftsentwicklung Enzyme bekannt Zwingenberg und Greifswald, 29. Mai 2024 – BRAIN Biotech AG und Enzymicals AG geben bekannt, dass Dr. Erik de Vries die BRAIN Biotech AG ab dem 1. Juni 2024 als Senior Business Development Director Enzymes unterstützen wird. Sein derzeitiges ......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.05.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG erhält wichtige Meilensteinzahlung und bleibt auf Kurs, um die kommunizierten Jahresziele zu erreichen
Article
News Preview
BRAIN Biotech AG erhält wichtige Meilensteinzahlung und bleibt auf Kurs, um die kommunizierten Jahresziele zu erreichen Bedeutende Meilensteinzahlung aus Pharma-Projekt in Höhe von 1,5 Mio. € erhalten BioProducts-Geschäftswachstum im 2. Quartal beschleunigt, weitere Beschleunigung in H2 erwartet Zielerreichung zum Ende des Geschäftsjahrs auf gut......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.05.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
Article
News Preview
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets  Major milestone payment from pharma-project of € 1.5 million received BioProducts business growth accelerated in Q2, further acceleration expected throughout H2 On-track to meet fiscal year end targets Significantly strengthened cash position Zwing......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.05.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
Article
News Preview
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets  Major milestone payment from pharma-project of € 1.5 million received BioProducts business growth accelerated in Q2, further acceleration expected throughout H2 On-track to meet fiscal year end targets Significantly strengthened cash position Zwing......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.04.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
Article
News Preview
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur Die BRAIN Biotech Gruppe wird zur weiteren Optimierung und Vereinfachung der Gruppenstruktur die AnalytiCon Discovery GmbH mit der BRAIN Biotech AG verschmelzen. Zwingenberg, 16. April 2024 – Der Vorstand der BRAIN Biotech AG hat mit Zustimmung des Aufsichtsrats eine......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.04.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG takes next step to optimize group structure
Article
News Preview
BRAIN Biotech AG takes next step to optimize group structure BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure. Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG, with the approval of the Supervisory Board, has resolved to merge......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.03.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Sustainable drinking pleasure based on agricultural side streams
Article
News Preview
Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and Provadis Hochschule jointly develop sustainable, non-alcoholic beverages from agricultural side streams Consortium reaps benefits of new grape varieties adapted to climate change Lif......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.03.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Nachhaltiger Trinkgenuss auf Basis landwirtschaftlicher Seitenströme
Article
News Preview
Getränke aus Weinblättern: Nachhaltiger Trinkgenuss auf Basis landwirtschaftlicher Seitenströme BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine und die Provadis Hochschule entwickeln gemeinsam nachhaltige, alkoholfreie Getränke aus landwirtschaftlichen Seitenströmen Konsortium nutzt Vorteile von neuen, an Klimawandel angepassten Re......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.03.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Ergebnisse der Hauptversammlung 2024 zum Finanzjahr 2022/23 der BRAIN Biotech AG
Article
News Preview
Ergebnisse der Hauptversammlung 2024 zum Finanzjahr 2022/23 der BRAIN Biotech AG Präsenzveranstaltung am Standort Zwingenberg Vorstand und Aufsichtsrat mit klarer Mehrheit entlastet Stille Beteiligungen des Landes Hessen mit sehr hoher Zustimmung beschlossen Zwingenberg, 12. März 2024 – In der Hauptversammlung der BRAIN Biotech AG (Frankfurter B......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.03.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
Article
News Preview
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG Face-to-face event at the Zwingenberg site Executive Board and Supervisory Board approved by a clear majority Silent partnership with the State of Hesse approved by a very large majority Zwingenberg, Germany, 12 March 2024 – At today´s Annual General Me......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.03.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Protein engineering successfully improves structural proteins for performance materials
Article
News Preview
Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials First patent application registered BRAIN Biotech relies on protein engineering expertise and bioinformatics for rational protein design Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading ......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.03.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Protein-Engineering verbessert erfolgreich Strukturproteine für Performance Materials
Article
News Preview
Zusammenarbeit von BRAIN Biotech und AMSilk: Protein-Engineering verbessert erfolgreich Strukturproteine für Performance Materials Erste Patentanmeldung bereits erfolgt BRAIN Biotech setzt auf Protein-Engineering-Expertise und Bioinformatik für rationales Protein-Design Zwingenberg / Neuried, 5. März 2024 – BRAIN Biotech AG, führender Anbieter v......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.02.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG platziert erfolgreich EUR 5,0 Mio. Wandelanleihe zur Finanzierung weiterer Wachstumsinitiativen
Article
News Preview
BRAIN Biotech AG platziert erfolgreich EUR 5,0 Mio. Wandelanleihe zur Finanzierung weiterer Wachstumsinitiativen Zwingenberg, 29. Februar 2024 – Der Vorstand der BRAIN Biotech AG hat in seiner heutigen Sitzung mit Zustimmung des Aufsichtsrats beschlossen, unter teilweiser Ausnutzung der von der ordentlichen Hauptversammlung am 8. März 2023 erteilt......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.02.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
Article
News Preview
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives Zwingenberg, Germany, 29 February 2024 – At its meeting today and with the approval of the Supervisory Board, the Management Board of BRAIN Biotech AG has resolved, to issue convertible bonds in the total nominal amount of EUR 5.0 ......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.02.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Issuance of EUR 5 million convertible bond with exclusion of subscription rights
Article
News Preview
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG: issuance of EUR 5 million converti......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.02.2024
ISIN: DE0005203947
Brain Biotechnology AG
BNN
LISTED
XETR
Begebung von Wandelschuldverschreibungen über EUR 5 Millionen unter Ausschluss des Bezugsrechts
Article
News Preview
NICHT ZUR VERTEILUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN DEN ODER IN DIE VEREINIGTEN STAATEN, AUSTRALIEN, KANADA, JAPAN ODER ANDERE LÄNDER, IN DER DIE VERTEILUNG ODER WEITERGABE GESETZLICH UNZULÄSSIG WÄRE. ES GELTEN ANDERE EINSCHRÄNKUNGEN. BITTE BEACHTEN SIE DIE WICHTIGEN HINWEISE AM ENDE DIESER MITTEILUNG. BRAIN Biotech AG: Begebung von Wan......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 17.01.2026, Calendar Week 03, 17th day of the year, 348 days remaining until EoY.